Richard P. Beckmann

Suggest Changes
Learn More
PURPOSE Selective inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) represents a promising therapeutic strategy. However, despite documented evidence of clinical activity, limited information(More)